KRT6A and ovarian carcinoma: The most significant different expression gene is upregulated FILIP1L, downregulated KRT6A and S100A14. While FILIP1L is a WNT pathway inhibitor [15], and the reduction of FILIP1L in ovarian cancer is associated with poor survival, progression and chemoresistance [30].